Universal Infant Immunisation Against Respiratory Syncytial Virus and European Inequalities: The Pandemics Lesson has not been Learnt

• 2023

  Sign in to bookmark this resource.

  Sign in
• Daniele De Luca; Manuel Sanchez-Luna; Karl Schettler; Louis Bont; Eugenio Baraldi
PMID: 37927432DOI: https://dx.doi.org/10.1016/j.lanepe.2023.100753

---

Access Resources

• Journal ArticleEN

About

The article discusses the importance of universal infant immunization against respiratory syncytial virus (RSV) in Europe to prevent severe respiratory infections in infants, reduce hospitalizations, and preserve pediatric intensive care unit (PICU/NICU) beds. Despite the approval of new immunization methods like nirsevimab, there are disparities in the implementation of immunization campaigns across European countries, with delays potentially impacting population immunity and healthcare resources. The article highlights the need for a coordinated, continent-wide approach to ensure efficient and timely immunization, emphasizing the urgency of addressing these barriers to protect infants and improve public health outcomes.

---

Tags

Hazard: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Antibodies, Monoclonal; Immunization; Infant; Intensive Care Units, Pediatric; Public Health; Respiratory Syncytial Virus Infections; Vaccination; Immunization Programs; Respiratory Syncytial Virus, Human; Healthcare Disparities

Institutions: Hôpital Antoine-Béclère AP-HP; Université Paris-Saclay; American College of Emergency Physicians; Hospital General Universitario Gregorio Marañón; St. Marien Children's Hospital; University Medical Centre Utrecht; Respiratory Syncytial Virus NETwork (ReSViNET) Foundation; University Hospital of Padova

---

More like this

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants 2023 · St. George's University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals Foundation NHS Trust, Sanofi, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris (AP-HP) Nirsevimab Binding-Site Conservation in Respiratory Syncytial Virus Fusion Glycoprotein Worldwide Between 1956 and 2021: An Analysis of Observational Study Sequencing Data 2023 · AstraZeneca, University Medical Center Utrecht Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions 2024 · University Medical Center Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---